PhaseBio Pharmaceuticals — Investor Presentation (August 2022)
32 slides from PhaseBio Pharmaceuticals's investor presentation, Aug 12, 2022
Slide 1: Corporate Overview August 2022
Corporate Overview August 2022
Slide 2: Forward-looking statements
This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str
Slide 3: Therapeutic Focus and Company Overview
Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiovascular diseases Product Candidates Bentracimab (PB2452) Novel agent in Phase 3 development for immediate and sustained reversal of ticagrelor, the preferred antipla
Slide 4: A Clinical Stage, Cardiovascular Focused Biopharmaceutical Company
Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity Q4 2022 Planned BLA submission PB6440 Resistant Hypertension 1H 2023 Submit Investigational New Drug application (IND) Partnering Opportunities Pemzivipt
Slide 5: Corporate
) Corporate
Slide 6: Experienced Management Team
6 Experienced Management Team JONATHAN MOW Chief Executive Officer SUSAN ARNOLD, PhD SVP Technical Operations GLEN BURKHARDT SVP Human Resources KRIS HANSON SVP & General Counsel JOHN LEE, MD, PhD, FACC Chief Medical Officer JOHN SHARP Chief Financial Officer JONATHAN BIRCHALL Chief Commercial Offic
Slide 7: Q2 2022 Financial Highlights
• Sub-license revenue: $0.2M • Operating expense: $25.5M R&D: $20.9M SG&A: $4.6M • Loss from operations: ($25.3M) • Net Loss of ($16.7M) or ($0.34) per share, basic and diluted 49.2M shares used for computing Q2 2022 net loss per share • Cash and cash equivalents as of 06/30/2022: $7.8M • Avai
Slide 8: Bentracimab (PB2452) Reversal Agent for Ticagrelor
Bentracimab (PB2452) Reversal Agent for Ticagrelor
Slide 9: P2Y12 Inhibitors: Unmet Need and the Dilemma in Managing Surgical Patients
Early surgery = Bleed risk P2Y12 Inhibitors: Unmet Need and the Dilemma in Managing Surgical Patients 9 5d - Ticagrelor washout2 Risk of bleeding Risk of thrombosis and procedural delay Bentracimab Later surgery = Thrombosis risk 1. Plavix/clopidogrel Prescribing Information: https://packageinserts.
Slide 10: Bentracimab: Novel Reversal Agent for Brilinta (Ticagrelor)
Bentracimab 10 • Ticagrelor has proven superior efficacy vs. clopidogrel and a unique reversible binding profile within the oral P2Y12 class Clopidogrel and prasugrel both permanently bind to the receptor and cannot be reversed • Bentracimab is the only specific reversal agent in development for t
Slide 11: Well-Characterized Mechanism of Reversal of Ticagrelor
BentracimabBentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor 11 1. 2. 3. 4. 5. ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation Bentracimab binds to free ticagrelor with very high affinity This is a reve
Slide 12: Clinical
Clinical
Slide 13: Immediate and Sustained Ticagrelor Reversal in Phase 1, 2A, 2B Trials
• Received ticagrelor + low-dose aspirin and bentracimab 18 g • Achieved primary endpoint of ticagrelor reversal measured by VerifyNow P2Y12 assay – Statistically significant reduction in % inhibition of PRU within 4 hours; similar extent of reversal to Phase 1 and 2A • Safety profile consistent wit
Slide 14: REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview
bentracimab 14 REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview • REVERSE-IT: Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial • Open-label, single-arm study in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure • To
Slide 15: REVERSE-IT: Baseline Characteristics
bentracimab REVERSE-IT: Baseline Characteristics 15https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047
Slide 16: REVERSE-IT: Platelet Reversal
bentracimab PRU analysis in surgical vs bleeding patients REVERSE-IT: Platelet Reversal 16 PRU analysis in all patients (N=150) (N=8) (N=142) https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047
Slide 17: REVERSE-IT: Adjudicated Surgical and Bleeding Hemostasis
bentracimab REVERSE-IT: Adjudicated Surgical and Bleeding Hemostasis 17 Adjudicated and Investigator-Reported Surgical Outcomes https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047 Adjudicated and Investigator-Reported Bleeding Outcomes
Slide 18: REVERSE-IT: No Platelet Rebound Activity and No Thrombotic Events
bentracimab P-selectin in surgical and bleeding patients Mean platelet volume in surgical and bleeding patientsEffect of Bentracimab Treatment on P- Selectin and Mean Platelet Volume (MPV). Soluble P-selectin and MPV were measured pre-dose and at multiple timepoints post-initiation of bentracimab tr
Slide 19: Regulatory
) Regulatory
Slide 20: Bentracimab Pre-BLA Meeting Summary
Bentracimab Pre-BLA Meeting Summary 20 • Type B pre biologics license application (pre-BLA) meeting held in April 2022 • PhaseBio proposed plans to submit a BLA with data from a total of 25-30 patients with uncontrolled bleeding, together with data from the fully-completed surgical cohort, to suppor
Slide 21: Bentracimab Development Program
Bentracimab Development Program 21 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteers CompletedPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive bentracimab N=150, major bleeding + urgent surgery patients Final N=200 PMC Completio
Slide 22: Opportunity for Accelerated/Conditional Approval
Bentracimab Opportunity for Accelerated/Conditional Approval 22 Planned Approval Packages Based on Phase 3 - Interim Analysis • Initial BLA/MAA filing package based on a minimum safety requirement of at least 100 Phase 3 patients • US: Accelerated (Based on biomarker) • EU: Conditional (Based on int
Slide 23: Commercial
) Commercial
Slide 24: Expect Continued Long-Term Rx Growth of Ticagrelor
Bentracimab Expect Continued Long-Term Rx Growth of Ticagrelor Bentracimab approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2021 were approximately $1.5B Pandemic impact dampened 2020 and 2021 growth • In February 2019, Brilinta Phase 3 THEMIS1 trial met
Slide 25: US Patients on P2Y12 Inhibitors: Potential for Ticagrelor Growth
BentracimabUS Patients on P2Y12 Inhibitors: Potential for Significant Long-Term Ticagrelor Patient Growth 25 0.4 3.8 0.2 2.02.2 0.2 Clopidogrel Prasugrel Ticagrelor US Patients on P2Y12 Inhibitors (millions) 2019 2029 (est.) Continued AZ Promotion Bentracimab Launch Brilinta Patent Expiry Potential
Slide 26: Patient Opportunity Implies $1-2B Addressable Market
Bentracimab Patient Opportunity (2019) Implies $1-2B* Addressable Market 439,1361 ticagrelor pts/year 4.46M1 total P2Y12 pts/year CABG, coronary artery bypass graft 91,833 (21%5) 26 Inpatient Urgent Surgery3 26,452 (6%5) Inpatient Semi-Elective Surgery4, 48,399 (11%5) ICH 1,698GI 6,623 Trauma 3,396
Slide 27: Mortality and Health-System Costs Associated with Surgical Bleeding
Increased Mortality and Health-System Costs Associated with Bleeding from Open Surgical Procedures Highlight Opportunity for Bentracimab 27 *All charges by the hospital for the inpatient episode – includes drugs, devices, professional fees, room and board etc. ‘Bleed’ = Moderate to Severe Bleeding i
Slide 28: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
Slide 29: PB6440 for Resistant Hypertension
PB6440 PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensive
Slide 30: PB6440: A Promising CYP11B2 Inhibitor
PB6440: A Promising CYP11B2 Inhibitor 30 Characteristics Of PB6440 High in vitro selectivity for CYP11B2 over CYP11B1 High in vitro selectivity for CYP11B2 over drug metabolizing and other steroidal CYPs High oral bioavailability Long half-life in vivo consistent with once-daily dosing Oral PK and s
Slide 31: PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2)
PB6440 CYP11B Potency and Selectivity (IC50, μM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699* 0.0007 0.013 19 0.016 0.059 3.7 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in
Slide 32: Resistant Hypertension: Large Market Opportunity
Resistant Hypertension (rHTN)1: Hypertensive patient on three or more antihypertensive medications and still above goal 32 Large market opportunity2 • ~75M hypertensives in the US • ~55M diagnosed and treated • ~10-15M resistant to treatment • Other potential indications include uncontrolled hyperte
PhaseBio Pharmaceuticals — Investor Presentation (August 2022) on 6ix